Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 39

1.

Fluticasone Furoate/Vilanterol (Breo Ellipta) [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016 Nov.

2.

Spotlight on fluticasone furoate/umeclidinium/vilanterol in COPD: design, development, and potential place in therapy.

Lal C, Strange C.

Int J Chron Obstruct Pulmon Dis. 2016 Dec 30;12:135-140. doi: 10.2147/COPD.S114273. eCollection 2017. Review.

3.

An algorithm recommendation for the pharmacological management of allergic rhinitis in the UK: a consensus statement from an expert panel.

Lipworth B, Newton J, Ram B, Small I, Schwarze J.

NPJ Prim Care Respir Med. 2017 Dec;27(1):3. doi: 10.1038/s41533-016-0001-y. Epub 2017 Jan 23. Review.

4.

Efficacy of tiotropium-olodaterol fixed-dose combination in COPD.

Derom E, Brusselle GG, Joos GF.

Int J Chron Obstruct Pulmon Dis. 2016 Dec 13;11:3163-3177. doi: 10.2147/COPD.S92840. eCollection 2016. Review.

5.

Spotlight on fluticasone furoate/vilanterol trifenatate for the once-daily treatment of asthma: design, development and place in therapy.

Albertson TE, Bullick SW, Schivo M, Sutter ME.

Drug Des Devel Ther. 2016 Dec 14;10:4047-4060. doi: 10.2147/DDDT.S113573. eCollection 2016. Review.

6.

Eosinophilic esophagitis in an octogenarian: A case report and review of the literature.

Trifan A, Stoica O, Chihaia CA, Danciu M, Stanciu C, Singeap AM.

Medicine (Baltimore). 2016 Oct;95(41):e5169. Review.

8.

Patient perspectives on fluticasone-vilanterol versus other corticosteroid combination products for the treatment of asthma.

Bollmeier SG, Prosser TR.

Patient Prefer Adherence. 2016 May 13;10:825-36. doi: 10.2147/PPA.S83946. eCollection 2016. Review.

9.

Chinese Herbal Medicine and Salmeterol and Fluticasone Propionate for Chronic Obstructive Pulmonary Disease: Systematic Review and Network Meta-Analysis.

Chung VC, Wu X, Ma PH, Ho RS, Poon SK, Hui DS, Wong SY, Wu JC.

Medicine (Baltimore). 2016 May;95(20):e3702. doi: 10.1097/MD.0000000000003702. Review.

10.

Eosinophilic Esophagitis: An Evidence-Based Approach to Therapy.

González-Cervera J, Lucendo AJ.

J Investig Allergol Clin Immunol. 2016;26(1):8-18; quiz 2p following 18. Review.

11.

Fluticasone furoate with vilanterol.

[No authors listed]

Aust Prescr. 2015 Feb;38(1):29-31. Epub 2014 Dec 1. Review. No abstract available.

12.

Achieving asthma control with ICS/LABA: A review of strategies for asthma management and prevention.

Aalbers R, Vogelmeier C, Kuna P.

Respir Med. 2016 Feb;111:1-7. doi: 10.1016/j.rmed.2015.11.002. Epub 2015 Nov 6. Review.

13.

Comparative safety and effectiveness of long-acting inhaled agents for treating chronic obstructive pulmonary disease: a systematic review and network meta-analysis.

Tricco AC, Strifler L, Veroniki AA, Yazdi F, Khan PA, Scott A, Ng C, Antony J, Mrklas K, D'Souza J, Cardoso R, Straus SE.

BMJ Open. 2015 Oct 26;5(10):e009183. doi: 10.1136/bmjopen-2015-009183. Review.

14.

Clinical role of dual bronchodilation with an indacaterol-glycopyrronium combination in the management of COPD: its impact on patient-related outcomes and quality of life.

Rossi A, Zanardi E, Poletti V, Cazzola M.

Int J Chron Obstruct Pulmon Dis. 2015 Jul 23;10:1383-92. doi: 10.2147/COPD.S55488. eCollection 2015. Review.

15.

Fluticasone-formoterol: a systematic review of its potential role in the treatment of asthma.

Prosser TR, Bollmeier SG.

Ther Clin Risk Manag. 2015 Jun 2;11:889-99. doi: 10.2147/TCRM.S55116. eCollection 2015. Review.

16.

Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan.

Horita N, Kaneko T.

Int J Chron Obstruct Pulmon Dis. 2015 Apr 21;10:813-22. doi: 10.2147/COPD.S56067. eCollection 2015. Review.

17.

Early chronic obstructive pulmonary disease: definition, assessment, and prevention.

Rennard SI, Drummond MB.

Lancet. 2015 May 2;385(9979):1778-88. doi: 10.1016/S0140-6736(15)60647-X. Review.

18.

Role of the fixed combination of fluticasone and salmeterol in adult Chinese patients with asthma and COPD.

Gao J, Pleasants RA.

Int J Chron Obstruct Pulmon Dis. 2015 Apr 15;10:775-89. doi: 10.2147/COPD.S80656. eCollection 2015. Review.

19.

Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD - mixed treatment comparisons of clinical efficacy.

Stynes G, Svedsater H, Wex J, Lettis S, Leather D, Castelnuovo E, Detry M, Berry S.

Respir Res. 2015 Feb 15;16:25. doi: 10.1186/s12931-015-0184-8. Review.

20.

Diagnosis and pharmacotherapy of stable chronic obstructive pulmonary disease: the finnish guidelines.

Kankaanranta H, Harju T, Kilpeläinen M, Mazur W, Lehto JT, Katajisto M, Peisa T, Meinander T, Lehtimäki L.

Basic Clin Pharmacol Toxicol. 2015 Apr;116(4):291-307. doi: 10.1111/bcpt.12366. Epub 2015 Jan 22. Review.

Supplemental Content

Loading ...
Support Center